UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate

Circulation (New York, N.Y.), 2015-01, Vol.131 (1), p.82-90

2015

Volltextzugriff (PDF)

Relative Bioavailability of Omaveloxolone When Capsules Are Sprinkled Over and Mixed in Applesauce Compared With Administration as Intact Omaveloxolone Capsules: A Phase 1, Randomized, Open‐Label, Single‐Dose, Crossover Study in Healthy Adults

Journal of clinical pharmacology, 2024-10, Vol.64 (10), p.1304-1311

2024

Volltextzugriff (PDF)

Pharmacokinetics of the Multi‐kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality

Clinical pharmacology in drug development, 2023-02, Vol.12 (2), p.159-167

2023

Volltextzugriff (PDF)

Evaluation of Potential Drug‐Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P‐Glycoprotein

Journal of clinical pharmacology, 2021-03, Vol.61 (3), p.298-306

2021

Volltextzugriff (PDF)

Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal

Critical care (London, England), 2016-09, Vol.20 (1), p.273-273, Article 273

2016

Volltextzugriff (PDF)

Effect of Mild and Moderate Hepatic Impairment (Defined by Child–Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics

Journal of clinical pharmacology, 2022-08, Vol.62 (8), p.992-1005

2022

Volltextzugriff (PDF)

Dosing Recommendation Based on the Effects of Different Meal Types on Pexidartinib Pharmacokinetics in Healthy Subjects: Implementation of Model‐informed Drug Development Strategy

Clinical pharmacology in drug development, 2023-05, Vol.12 (5), p.475-483

2023

Volltextzugriff (PDF)

Understanding the mechanisms of food effect on omaveloxolone pharmacokinetics through physiologically based biopharmaceutics modeling

CPT: pharmacometrics and systems pharmacology, 2024-10, Vol.13 (10), p.1771-1783

2024

Volltextzugriff (PDF)

Effect of coadministration of metformin with mirogabalin: Results from a phase 1, randomized, open-label, drug-drug interaction study

International journal of clinical pharmacology and therapeutics, 2018-10, Vol.56 (10), p.451-458

2018

Volltextzugriff (PDF)

Phase I studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of DS‐1211, a tissue‐nonspecific alkaline phosphatase inhibitor

Clinical and translational science, 2022-04, Vol.15 (4), p.967-980

2022

Volltextzugriff (PDF)

Exposure–response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor

CPT: pharmacometrics and systems pharmacology, 2021-11, Vol.10 (11), p.1422-1432

2021

Volltextzugriff (PDF)

Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects

Thrombosis and haemostasis, 2012-07, Vol.108 (1), p.166-175

2012

Volltextzugriff (PDF)

Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies

Pharmacology research & perspectives, 2018-10, Vol.6 (5), p.e00418-n/a

2018

Volltextzugriff (PDF)

Abuse potential of mirogabalin in recreational polydrug users

Therapeutic advances in drug safety, 2019, Vol.10, p.2042098619836032-2042098619836032

2019

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Mirogabalin When Coadministered With Lorazepam, Zolpidem, Tramadol, or Ethanol: Results From Drug‐Drug Interaction Studies in Healthy Subjects

Clinical pharmacology in drug development, 2018-08, Vol.7 (6), p.597-612

2018

Volltextzugriff (PDF)

Metabolism and disposition of [14C]tivantinib after oral administration to humans, dogs and rats

Xenobiotica, 2014-11, Vol.44 (11), p.996-1008

2014

Volltextzugriff (PDF)

Development and validation of an HPLC-UV method for determination of iohexol in human plasma

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2005-02, Vol.816 (1), p.339-343

2005

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics, and Safety of Edoxaban in Pediatric Subjects: A Phase I Single‐Dose Study

Clinical pharmacology and therapeutics, 2024-09, Vol.116 (3), p.736-746

2024

Volltextzugriff (PDF)

Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine

British journal of clinical pharmacology, 2016-12, Vol.82 (6), p.1591-1600

2016

Volltextzugriff (PDF)

Tacrolimus in diabetic kidney transplant recipients: pharmacokinetics and application of a limited sampling strategy

Therapeutic drug monitoring, 2007-08, Vol.29 (4), p.391-398

2007

Volltextzugriff (PDF)

Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2013-10, Vol.13 (5), p.331-342

2013

Volltextzugriff (PDF)

Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients

Therapeutic drug monitoring, 2005-08, Vol.27 (4), p.422-430

2005

Volltextzugriff (PDF)

Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects

Clinical pharmacokinetics, 2022-11, Vol.61 (11), p.1623-1639

2022

Volltextzugriff (PDF)

Changes in tacrolimus distribution in blood and plasma protein binding following liver transplantation

Therapeutic drug monitoring, 2004-10, Vol.26 (5), p.506-515

2004

Volltextzugriff (PDF)

Apparent clearance of sirolimus in heart transplant recipients: impact of primary diagnosis and serum lipids

Therapeutic drug monitoring, 2006-10, Vol.28 (5), p.614-622

2006

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(54)

Sprache

Englisch
(54)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate

Relative Bioavailability of Omaveloxolone When Capsules Are Sprinkled Over and Mixed in Applesauce Compared With Administration as Intact Omaveloxolone Capsules: A Phase 1, Randomized, Open‐Label, Single‐Dose, Crossover Study in Healthy Adults

Pharmacokinetics of the Multi‐kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality

Evaluation of Potential Drug‐Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P‐Glycoprotein

Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal

Effect of Mild and Moderate Hepatic Impairment (Defined by Child–Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics

Dosing Recommendation Based on the Effects of Different Meal Types on Pexidartinib Pharmacokinetics in Healthy Subjects: Implementation of Model‐informed Drug Development Strategy

Understanding the mechanisms of food effect on omaveloxolone pharmacokinetics through physiologically based biopharmaceutics modeling

Effect of coadministration of metformin with mirogabalin: Results from a phase 1, randomized, open-label, drug-drug interaction study

Phase I studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of DS‐1211, a tissue‐nonspecific alkaline phosphatase inhibitor

Exposure–response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor

Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects

Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies

Abuse potential of mirogabalin in recreational polydrug users

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Mirogabalin When Coadministered With Lorazepam, Zolpidem, Tramadol, or Ethanol: Results From Drug‐Drug Interaction Studies in Healthy Subjects

Metabolism and disposition of [14C]tivantinib after oral administration to humans, dogs and rats

Development and validation of an HPLC-UV method for determination of iohexol in human plasma

Pharmacokinetics, Pharmacodynamics, and Safety of Edoxaban in Pediatric Subjects: A Phase I Single‐Dose Study

Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine

Tacrolimus in diabetic kidney transplant recipients: pharmacokinetics and application of a limited sampling strategy

Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor

Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients

Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects

Changes in tacrolimus distribution in blood and plasma protein binding following liver transplantation

Apparent clearance of sirolimus in heart transplant recipients: impact of primary diagnosis and serum lipids

Suchergebnisse filtern